All In Biotech

Drug Trial Radar · NCT01896232

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism

Last checked: Nov 20, 2026Latest source record: Jul 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 683 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

683

Actual

Start

Aug 13, 2013

Primary completion

Nov 12, 2014

Study completion Jan 8, 2015

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jul 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum parathyroid hormone (PTH) levels by \> 30% from baseline among patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) who require management with hemodialysis.

Conditions

  • Secondary Hyperparathyroidism
  • Chronic Kidney Disease

Interventions

  • EtelcalcetideDrug

    Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.

  • CinacalcetDrug

    Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.

  • Oral PlaceboDrug

    Administered orally once a day.

  • Intravenous PlaceboDrug

    Administered intravenously (IV) three times per week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With > 30% Reduction From Baseline in Mean Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority AnalysisTime frame: Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).

Locations

182 sites in 22 countries. Site status is shown where the registry gives one.

  • Research Site

    Azusa, California

  • Research Site

    Bakersfield, California

  • Research Site

    Bakersfield, California

  • Research Site

    Chula Vista, California

  • Research Site

    Covina, California

  • Research Site

    Granada Hills, California

  • Research Site

    La Mesa, California

  • Research Site

    La Puente, California

  • Research Site

    Los Angeles, California

  • Research Site

    San Diego, California

  • Research Site

    San Gabriel, California

  • Research Site

    Whittier, California

  • Research Site

    Arvada, Colorado

  • Research Site

    Aurora, Colorado

  • Research Site

    Longmont, Colorado

  • Research Site

    Westminster, Colorado

  • Research Site

    Orange, Connecticut

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Pinecrest, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Lafayette, Louisiana

  • Research Site

    Southgate, Michigan

  • Research Site

    Columbus, Mississippi

  • Research Site

    Gulfport, Mississippi

  • Research Site

    Sewell, New Jersey

  • Research Site

    Great Neck, New York

  • Research Site

    Mineola, New York

  • Research Site

    Ridgewood, New York

  • Research Site

    Rosedale, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Wilmington, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Burlington, Vermont

  • Research Site

    Fairfax, Virginia

  • Research Site

    Portsmouth, Virginia

Showing 40 of 182 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.